TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05174312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reprieve Decongestion Management System
Description: The Reprieve Decongestion Management System, or Reprieve DMS, is a hospital bedside fluid management console designed to provide personalized and automated infusion of the IV diuretic furosemide and physiological saline in response to the patient's real-time urine output to safely and rapidly decongest patients suffering from Acute Decompensated Heart Failure.
Study: NCT06164795

Intervention type: DRUG
Intervention: Denosumab
Description: subcutaneous injection

Intervention type: DRUG
Intervention: Teriparatide
Description: subcutaneous injection

Intervention type: DRUG
Intervention: Romosozumab
Description: subcutaneous injection
Study: NCT05544825

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ice plant group
Description: Ice plant extract 2,000 mg/day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Placebo 2,000 mg/day for 12 weeks
Study: NCT05174312

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diuretic
Description: Best practices of optimal diuretic dosing such as those demonstrated in recent randomized trials (DOSE, ADVOR, CLOROTIC).
Study: NCT04852601

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ToolboxDetect
Description: The clinician or staff member will identify the patient by either scanning a barcode or entering his/her name, age and medical record number on an administrative screen (allowing for proper routing of test results). After completing the test, a 'submit' button will automatically generate a secure HL7 message, sharing 1) a binary classification of the results ('impaired cognition' or 'normal function'), 2) the quantitative ToolboxDetect score, and 3) brief clinical decision support to rule out any reversible causes. These results will be linked to a discrete, queriable, Epic SmartData element. As patients undergo multiple AWVs over time, ToolboxDetect quantitative scores will be displayed in Epic Synopsis Activity, a graphical display that can visualize trend data (e.g. patient vitals) and calculate a percentage change from the prior year. This will allow a clinician to establish a patient's own baseline (instead of using normative data only) for reference.
Study: NCT06671054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP1189, 40 mg
Description: AP1189 tablets for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP1189, 70 mg
Description: AP1189 tablets for oral use
Study: NCT06175663

Intervention type: DRUG
Intervention: Antihypertensive medication withdrawal
Description: To determine if high blood pressure is caused by an overproduction of aldosterone in the adrenal gland (i.e. primary hyperaldosteronism), the plasma aldosterone/renin ratio (ARR) can be determined. Because many common hypertensive drugs are known to interfere with this ratio, patients often have to discontinue drugs prior to screening or switch to drugs that are known not to affect ARR (i.e. doxazosin, verapamil, diltiazem, hydralazine). Drugs have to be stopped for at least four weeks (for mineralocorticoid receptor antagonists) or two weeks (for diuretics, Angiotensin Converting Enzyme (ACE) inhibitors, Angiotensin Receptor Blockers (ARBs)). This often leads to a temporary increase in blood pressure. After diagnostics are completed, medication is adjusted accordingly and blood pressure levels drop again.
Study: NCT05655065

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: increase of mean arterial pressure at 65-70 mmHg
Description: Increase of mean arterial pressure at 65-70 mmHg (with catecholamines or volemic expansion at the discretion of the clinician)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: increase of mean arterial pressure at 80-85 mmHg
Description: Increase of mean arterial pressure at 80-85mmHg (with catecholamines or volemic expansion at the discretion of the clinician).
Study: NCT04846062

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: nutrition behavior intervention
Description: Iodized salt utilization and iron dietary intake behavior

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: nutrition behavior intervention
Description: Iodized salt utilization and iron dietary intake behavior
Study: NCT06086002

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microwave ablation
Description: Microwave ablation will be performed by using single antenna (Emprint, Medtronic) with overlapping ablation or two antennas (Starwave, STARmed) with simultaneous ablation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microwave ablation
Description: Microwave ablation will be performed by using single antenna (Emprint, Medtronic) with overlapping ablation or two antennas (Starwave, STARmed) with simultaneous ablation.
Study: NCT06671054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP1189, 100 mg
Description: AP1189 tablets for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP1189 matching placebo
Description: AP1189 tablets for oral use
Study: NCT05471349

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Flyer and video
Description: Participants will view a flyer and video

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Flyer and video
Description: Participants will view a flyer and video

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Flyer and video
Description: Participants will view a flyer and video
Study: NCT05320237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality Intervention
Description: Eight week intervention with two sessions a week. Each session will be 30 minutes in duration and will involve participants partaking in VR and such games include targeting individual finger movement (playing piano); grasp and release and one game (catching falling stars) includes holding a controller for elbow flexion and extension (Whack-a-mole).
Study: NCT06628037

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SN514-066b
Description: Enzyme debrider

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SN514-066b
Description: Enzyme debrider

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SN514-066b
Description: Enzyme debrider

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SN514-066b
Description: Enzyme debrider
Study: NCT06628154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan potassium 50mg
Description: Single dose losartan (50 mg, weight-adjusted), encapsulated identically to placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single tablet encapsulated identically to losartan
Study: NCT06486389

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: reading fairy tales
Description: Reading fairy tales during inhaler medication administration.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: painting
Description: painting during inhaler medication administration
Study: NCT05993390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Intravenous administration of sugammadex 2mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine
Description: Intravenous administration of neostigmine 0.05mg/kg with glycopyrrolate 0.01mg/kg
Study: NCT04651816

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives
Description: Participants will be entered into a lottery to receive a gift card for class attendance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives
Description: Participants will be entered into a lottery to receive a gift card for class attendance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Message
Description: Participants will be sent motivational messages through out their participation in the PSH DPP program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DPP Program
Description: All Participants will be enrolled in the DPP program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DPP Program
Description: All Participants will be enrolled in the DPP program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DPP Program
Description: All Participants will be enrolled in the DPP program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DPP Program
Description: All Participants will be enrolled in the DPP program.
Study: NCT06250439

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECMO-Flow variations
Description: The protocol unfolds in 5 steps as follows, each step lasting between 10 and 15 minutes to allow for the patient's hemodynamic adaptation. At each step, invasive and non-invasive hemodynamic evaluation is performed.~1. The 1st step is called 100% flow: it involves recording the patient's hemodynamic measurements at the baseline, i.e., at 100% of their ECMO-VA flow, previously set by the clinician entirely independently of the study.~2. The 2nd step is called 125% flow: the patient's ECMO-VA flow is increased to 125% of the initial flow.~3. The 3rd step is called 150% flow: the patient's ECMO-VA flow is increased to 150% of the initial flow.~4. The 4th step is called 175% flow: the patient's ECMO-VA flow is increased to 175% of the initial flow.~5. The 5th and final step is called 200% flow: the patient's ECMO-VA flow is increased to 200% of the initial flow.
Study: NCT05063591

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transfusion support
Description: Patients will be offered symptom-driven transfusion support in addition to standard hospice care
Study: NCT06323616

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MAC adjustment to PSI between 25 and 50
Description: According to SedLine monitoring, the depth of anesthesia will be adjusted by changing the amount of sevoflurane so that the PSI median value is between 25 and 50.
Study: NCT06675240

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MediNF
Description: Over 10-sessions participants will engage in a breath-focused meditative practice with frontal brain connectivity neurofeedback provided to enhance performance.
Study: NCT06673953

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory Muscle Training by (The Breather)
Description: Patients are instructed to inhale deeply and forcefully (at non fatigable resistance) for 2-3 seconds, slight pause, and then exhale forcefully for 2-3 seconds for 10 repetitions with 2 sets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional physical therapy program
Description: Traditional physical therapy program in form of: (TENS / Low-intensity continuous ultrasonic / Infrared radiation application / Cervical Stabilization exercise )

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physical therapy program
Description: Traditional physical therapy program in form of: (TENS / Low-intensity continuous ultrasonic / Infrared radiation application / Cervical Stabilization exercise )
Study: NCT05483140

Intervention type: OTHER
Intervention: Option 1
Description: Partial meal replacement to achieve 900-1000 kcal/day (4 meal replacement products per day combined with 150-200 kcal from vegetable meals (recipes provided))

Intervention type: OTHER
Intervention: Option 2
Description: Partial meal replacement to achieve 900-1000 kcal/day (2 meal replacement products per day combined with one balanced meal (recipes provided))

Intervention type: OTHER
Intervention: Option 3
Description: A real food low energy diet to achieve 800-1000 kcal/day (recipes provided)
Study: NCT06679452

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emotion-Focused Therapy
Description: This feasibility protocol is a two-arm, parallel, double-blinded, RCT aimed at informing a future trial assessing the effectiveness of EFT in resolving emotional injuries in older adults in the context of interpersonal offenses.
Study: NCT04427722

Intervention type: DEVICE
Intervention: MPS-Flex Total Knee Joint Prostheses
Description: Patients who have received MPS-Flex Total Knee Joint Prostheses for their primary TKA and meet the Patient Selection Criteria outlined in the study protocol.
Study: NCT04805567

Intervention type: DEVICE
Intervention: endocuff
Description: The Endocuff is a device that can be mounted on the tip of an endoscope and may assist to inspect a greater surface of the colonic mucosa by pulling backwards, flattening, and stretching the colonic folds as the endoscope is gradually withdrawn.
Study: NCT06681194

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver Nitrate
Description: See Silver nitrate only study arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triamcinolone
Description: See Triamcinolone only study arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver nitrate + triamcinolone
Description: See Combination group study arm
Study: NCT06290687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemotherapy
Description: Standard of care neoadjuvant systemic therapy is currently cisplatin-based chemotherapy in cisplatin-eligible participants. Participants will start treatment within 60 days of Transurethral Resection of Bladder Tumor. Regimens may include:~* Cisplatin - Gemcitabine (Gem/Cis)~* Dose Dense Methotrexate - Vinblastine - Adriamycin - Cisplatin (MVAC)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial cystectomy with Extended pelvic lymph node dissection
Description: Partial cystectomy will then be performed using the surgical technique at the discretion of the treating Urologic Oncologist. Extended pelvic lymphadenectomy will then be performed at the discretion of the treating Urologic Oncologist. Surgery will be performed within 60 days of Transurethral Resection of Bladder Tumor for Cisplatin-ineligible participants. Surgery will be performed within 60 days of completing neoadjuvant chemotherapy for Cisplatin-eligible participants.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial cystectomy with Extended pelvic lymph node dissection
Description: Partial cystectomy will then be performed using the surgical technique at the discretion of the treating Urologic Oncologist. Extended pelvic lymphadenectomy will then be performed at the discretion of the treating Urologic Oncologist. Surgery will be performed within 60 days of Transurethral Resection of Bladder Tumor for Cisplatin-ineligible participants. Surgery will be performed within 60 days of completing neoadjuvant chemotherapy for Cisplatin-eligible participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant systemic therapy
Description: Standard of care adjuvant systemic therapy in eligible participants. The choice of adjuvant systemic therapy will be left to the discretion of the treating Medical Oncologist but must fall within the SOC as outlined in NCCN guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant systemic therapy
Description: Standard of care adjuvant systemic therapy in eligible participants. The choice of adjuvant systemic therapy will be left to the discretion of the treating Medical Oncologist but must fall within the SOC as outlined in NCCN guidelines.
Study: NCT06685679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: oral melatonin 3 mg/kg/day divided in 3 doses , after enteral feeding, for 3 consecutive days, as combined therapy to milrinone
Study: NCT06488729

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot massage
Description: Foot massage
Study: NCT06685679

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Equivalent amount of distilled water will be given every hours as combined therapy to milrinone
Study: NCT06683924

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed Radiofrequency Ablation
Description: The area where the lateral femoral cutaneous nerve is seen with US will be anesthetized with 1 ml of 1% lidocaine and a 22 Gauge, 10 cm-5 mm RF cannula will be inserted. Sensory fibers will be stimulated with 0.3-0.5 V. Then, motor fibers will be stimulated up to 1.5 V. If no motor contraction is seen, LFCN will be ablated at 42 degrees Celsius for 240 seconds. The procedure will be completed with the injection of 2 ml of 2% lidocaine and 2 ml (8 mg) dexamethasone through the RF cannula.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid (dexamethasone) Injection
Description: Where the lateral femoral cutaneous nerve is visible with US, 2 ml of 2% lidocaine and 2 ml (8 mg) dexamethasone will be injected.
Study: NCT06682975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZP9830
Description: Participants will receive 1 single dose of ZP9830 given subcutaneously (s.c., under the skin) or intravenously (i.v., in a vein of the arm). Dose level will depend on the cohort.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive 1 single dose of placebo given subcutaneously (s.c., under the skin) or intravenously (i.v., in a vein of the arm). Volume will be matching the active treatment
Study: NCT06687239

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blinded estimation of fetal weight
Description: Blinded ultrasound-based estimation of fetal weight

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Non blinded estimation of fetal weight
Description: Non-blinded ultrasound-based estimation of fetal weight
Study: NCT06687382

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MBK-01
Description: Initial dose of 4 capsules of MBK-01 (heterologous lyophilized intestinal microbiota coming from healthy donors) orally the first day, followed by a single daily capsule during 16 days. Participants will receive a total dose of 20 capsules of MBK-01.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MBK-01
Description: Initial dose of 4 capsules of MBK-01 (heterologous lyophilized intestinal microbiota coming from healthy donors) orally the first day, followed by a single daily capsule for 16 days and a maintenance dose 3 months after the ending of the initial dose. The maintenance dose is administered the same as the initial dose: 4 capsules of MBK-01 orally the first day, followed by a single daily capsule for 16 days. Participants will receive a total dose of 40 capsules of MBK-01.
Study: NCT06686732

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal physiotherapy
Description: Experimental group included cold pack over lateral epicondyle. Passive stretching exercises in trapezius and levator scapulae and upper ECRB,ECRL,ECU,Extensor Digitorum, Extensor Digiti Minimi. Eccentric exercise of the extensor muscles associated with mobilization with movement. Neuromusclar Rehabilitation Excersise. In the region of origin of the tendons of the extensor muscles of the wrist and fingers for 2 min and inhibition of points of tension in the belly of the extensor region. Early mobilization with movement with the wrist in extension. Lateral sustained glide will be give at humeroradial joint during movement.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: Control group included Cold pack for 10 mins on the lateral epicondylitis, Extensor carpi radialis brevis stretching (hold for 15 seconds x 4 reps) Active ROM of wrist flexion and extension (10 reps x 3 sets) Active ROM of elbow flexion, extension, supination and pronation (10 reps x 3 sets) . Manually resisting wrist extensors (10 second hold x 5 reps x 3 sets) 4 sets of Maitland elbow joint mobilization with 1 min of rest between sets. Baseline Dynamometer for grip strength and VAS for pain. These pre and post intervention values were mentioned in questionnaire. The participants were administered with the protocol and data was collected again immediately after the interventions without any delay.
Study: NCT06687811

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: preoperative carbohydrate loading
Description: Patients receive 200 ml drink containing Maltodextrin 12.5%, 2 hours prior to surgery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receive 200 ml regular drinking water with zero-calorie sweetener, 2 hours prior to surgery
Study: NCT06686043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPV vaccine, Imiquimod, and metformin combination therapy
Description: Participants in the treatment arm will have visits during the 2nd and 4th weeks of radiation, and then at weeks 8, 10, 12, and 16 after radiation. At each visit, a blood sample will be taken, and tumor cells collected using a cytobrush (or directly from the tumor for vulvar cancer). An HPV vaccine will be injected into the tumor, imiquimod cream will be applied topically, and participants will receive a subcutaneous vaccine shot. They will also take metformin tablets twice daily for two weeks and apply imiquimod cream at home three nights per week. Follow-up PET/CT scans will occur at week 20 and two years post-treatment, with exams every three months for two years.
Study: NCT06689631

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Respiratory Physiotherapy
Description: Mucociliary clearance techniques (prolonged slow expiration and provoked cough), bronchodilator when prescribed and nebulisation with 3% hypertonic saline.
Study: NCT06690229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glass ionomer cement
Description: A cement used for crown cementation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: self-adhesive resin cement
Description: A cement used for crown cementation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: resin modified glass ionomer cement
Description: A cement used for crown cementation
Study: NCT06685978

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Xiang Ju Ru Pi Ning capsule Placebo
Description: Xiang Ju Ru Pi Ning capsule Placebo(0.45g per capsule ) 4 capsules each time,p.o.,tid,for 3menstrual cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiang Ju Ru Pi Ning capsule
Description: Xiang Ju Ru Pi Ning capsule (0.45g per capsule ) 4 capsules each time,p.o.,tid,for 3menstrual cycle.